Application of conditionally replicating herpes vector for gene therapy treatment of urologic neoplasms.
Herpes vector has been widely used for experimental gene therapy. We herein review the strategies of such therapy for the treatment of urologic neoplasms. Most experimental studies of genetically altered viruses have employed replication-incompetent vectors. However, such viruses are unable to infect additional cells subsequent to the initial infection event. Therefore, this strategy has relied heavily on the bystander effect because a large number of noninfected tumor cells remain. Conditionally replicating herpes vector G207 has been developed in order to overcome potential problems of safety and tumor specificity for human use. It has been used to treat malignant brain tumors because of its neural tropism. In the last few years, applications of G207 for non-neural tumors have been reported. Because G207 may be useful for the treatment of urologic malignant tumors, we evaluated the antitumor effect against several types of tumor cells both in vitro and in vivo. Our data suggest that G207 may be applicable for the treatment of urologic malignant tumors.
Oyama
M
M
Department of Urology, School of Medicine, Keio University, Tokyo, Japan. moyama@med.keio.ac.jp
Yazaki
T
T
Ohigashi
T
T
Hoshi
M
M
Horiguchi
Y
Y
Oya
M
M
Asakura
H
H
Nakashima
J
J
Tachibana
M
M
Uyemura
K
K
Murai
M
M
D000818:Animals; D015316:Genetic Therapy; D005822:Genetic Vectors; D006564:Herpesviridae / Q000235:genetics* / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D014571:Urologic Neoplasms / Q000235:genetics / Q000628:therapy*; D014779:Virus Replication